某些修饰尿核苷对乳腺癌的预后意义。

Breast cancer prognostic significance of some modified urinary nucleosides.

作者信息

Sasco A J, Rey F, Reynaud C, Bobin J Y, Clavel M, Niveleau A

机构信息

Program of Epidemiology for Cancer Prevention, International Agency for Research on Cancer, Lyon, France.

出版信息

Cancer Lett. 1996 Nov 29;108(2):157-62. doi: 10.1016/s0304-3835(96)04393-5.

DOI:10.1016/s0304-3835(96)04393-5

PMID:8973589

Abstract

The prognostic significance of six urinary modified nucleosides, 5-methylcytidine (5-MeCyd), 4-acetylcytidine (4-AcCyd), 1-methylinosine (1-MeIno), 1-methyladenosine (1-MeAdo), 7-methylguanosine (7-MeGua) and pseudouridine (psi-Urd) was evaluated in 68 breast cancer patients of the specialized cancer hospital of Lyon (France). Excretions of 1-MeIno and 1-MeAdo were significantly higher in patients hospitalized in the medical rather than surgical ward, reflecting more advanced disease, and also among patients who died within 5 years of follow-up as compared to those still alive. These results suggest an unfavourable prognostic significance of high urinary excretion of 1-MeIno and 1-MeAdo in breast cancer patients.

摘要

在法国里昂专科医院的68例乳腺癌患者中，评估了六种尿修饰核苷，即5-甲基胞苷（5-MeCyd）、4-乙酰胞苷（4-AcCyd）、1-甲基肌苷（1-MeIno）、1-甲基腺苷（1-MeAdo）、7-甲基鸟苷（7-MeGua）和假尿苷（psi-Urd）的预后意义。在医疗病房而非外科病房住院的患者中，1-MeIno和1-MeAdo的排泄量显著更高，这反映了疾病进展更严重，并且在随访5年内死亡的患者中，与仍存活的患者相比，其排泄量也更高。这些结果表明，乳腺癌患者尿中1-MeIno和1-MeAdo排泄量高具有不良预后意义。